Impact of Von Willebrand Factor and Its Multimers on Angiogenesis

Recruiting

• Conditions: Von Willebrand Diseases
• Interventions: Other: no intervention

• Registration Number: NCT04810702
• Lead Sponsor: Nantes University Hospital

Brief Summary

The study aims to study the expression of numerous proteins involved in angiogenesis in 70 patients with von Willebrand disease in order to try to identify markers of interest. Secondly, the investigators plan to investigate whether there is a relationship between the proteins tested, the distribution of multimers and the clinical phenotype of the patients, in particular by looking for the presence of bleeding linked to the presence of angiodysplasias.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-03-16
• Study First Submitted QC: 2021-03-19
• Study First Posted: 2021-03-23
• Study Start: 2024-02-07
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-20
• Last Update Posted: 2024-03-22
• Primary Completion: 2024-08-07
• Study Completion: 2024-08-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

For patients:

• Patient with von Willebrand disease proven by genetic analysis of the VWF gene.
• Lack of treatment that could interfere with angiogenesis.
• Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.

For the control:

• Patient with a normal coagulation report
• Absence of abnormal hemorrhagic symptoms
• Lack of notion of angiodysplasia.
• Lack of treatment that could interfere with angiogenesis.
• Patient informed by an information note sent to his home, with the possibility of objecting to the use of his blood samples in the context of research.

Exclusion Criteria

• Patient under guardianship or curatorship.
• Pregnant and lactating women.
• Blood transfusion or treatment with von Willebrand factor concentrates less than 7 days old.
• Treatment which may interfere with angiogenesis.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
patients with von Willebrand disease	no intervention	-
case control	no intervention	-

Primary Outcome Measures

Name	Time	Method
To study the relationship between proteins involved in angiogenesis and the distribution of multimers in patients with von Willebrand disease in order to define markers of interest	1 year	Compare the distribution of protein assays between different groups of patients and the control group

Secondary Outcome Measures

Name	Time	Method
To study the relationship between the distribution of multimers and the clinical phenotype of patients, and in particular the presence of angiodysplasias	1 year	To study the correlation between the clinical phenotype and the assays of angiogenesis proteins
To study the relationship between the markers of interest and the clinical phenotype of patients, and in particular the presence of angiodysplasias	1 year	To study the correlation between the clinical phenotype and the distribution of multimers

Trial Locations

Locations (1)

CHU de Nantes; 🇫🇷 Nantes, France